Ioannis Toliopoulos
University of Ioannina
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Ioannis Toliopoulos.
Redox Report | 2012
Yannis V. Simos; Ioannis I. Verginadis; Ioannis Toliopoulos; Anastasia P. Velalopoulou; Ilias V Karagounis; Spyridon Karkabounas; Angelos Evangelou
Abstract Objectives The objective of this study was to investigate the effects of catechin and epicatechin on the activity of the endogenous antioxidant enzymes superoxide dismutase (SOD) and glutathione peroxidase (GPx) (as well as the total antioxidant capacity (TAC)) of rats after intra-peritoneal (i.p.) administration. Methods Twenty-four Wistar rats were randomly divided into two groups: the experimental group which was administered daily with a 1:1 mixture of epicatechin and catechin at a concentration of 23 mg/kg body weight for 10 days and the control group which was injected daily with an equal amount of saline. Blood and urine samples were collected before and after the administration period, as well as 10 days after (follow-up). Results Intra-peritoneal administration of catechins led to a potent decrease in GPx levels and a significant increase in SOD levels. TAC was significantly increased in plasma and urine. Malonaldehyde levels in urine remained stable. In the animals treated with catechins, SOD activity showed a moderate negative correlation with GPx activity. Discussion Boosting the activity of the antioxidant enzymes could be a potential adjuvant approach for the treatment of the oxidative stress-related diseases.
Cell Biochemistry and Function | 2013
Ioannis Toliopoulos; Yannis V. Simos; Dimitrios Bougiouklis; Stergios Oikonomidis
The present study was designed in order to evaluate the effects of five homoeopathic complex preparations on functional activity natural killer cells (NKCs) in advanced cancer patients. We examined the effects of Coenzyme Compositum®, Ubichinon Compositum®, Glyoxal Compositum®, Katalysatoren® and Traumeel® on the functional activity of NKCs. Experimental procedures included in vitro and in vivo trials. The in vitro trials were performed in NKCs isolated from 12 healthy volunteers (aged 44 ± 4 years) and incubated with the five homoeopathic complex preparations. The in vivo trials were performed in 15 advanced cancer patients (aged 55 ± 12 years) supplemented for 3 months with the homoeopathic preparations. All five homoeopathic preparations significantly increased the cytotoxic activity of the NKCs at the lowest NKCs/target cell ratio 12:1 (p < 0·05). The order of activity was: Ubichinon Compositum® > Glyoxal Compositum® > Katalysatoren® > Traumeel® > Coenzyme Compositum®. In the advanced cancer patients, the homoeopathic preparation significantly increased NKCs cytotoxic activity (p < 0·05). The homoeopathic complex preparations tested in this study can be used as an adjuvant immunotherapy in advanced cancer patients. Copyright
Journal of Musculoskeletal Research | 2017
Stergios Oikonomidis; Yannis V. Simos; Ioannis Toliopoulos; Ioannis I. Verginadis; Alexandros S. Oikonomidis; Vasilios Ragos; Spyridon Karkabounas; Angelos Evangelou; Dimitrios Peschos
The aim of the study was to examine the incidence of oxidative stress on the severity of knee osteoarthritis (OA). Data were obtained from a previous pilot controlled trial among patients, diagnosed with OA in one or both knees, that were randomly assigned into two different treatment groups and were either supplemented with ascorbic acid and Vitamin E daily per os or treated with meloxicam. The following markers were estimated: A. Clinical markers: functionality of the knee (WOMAC index), pain (using a pain visual analogue scale) and severity of OA (Kellgren–Lawrence grading scale) B. Laboratory markers: total antioxidant capacity (TAC) and malonyldialdehyde (MDA) levels in the synovial fluid. The TAC of the knees was moderately correlated with the severity of OA and the level of pain whilst MDA concentration was weekly correlated. An average change of 5mM of a-tocopherol in TAC (4.6–5.5mM of a-tocopherol) defines the shift among stages of OA and the level of pain experienced by the patients. Neither TAC...
Indian Journal of Biochemistry & Biophysics | 2013
Ioannis Toliopoulos; Yannis V. Simos; Stergios Oikonomidis; Spyros Karkabounas
Indian Journal of Experimental Biology | 2011
Ioannis Toliopoulos; Yannis V. Simos; Telemachos Daskalou; Ioannis I. Verginadis; Angelos Evangelou; Spyros Karkabounas
Journal of Herbal Medicine | 2012
Ioannis Toliopoulos; Yannis V. Simos; Ioannis I. Verginadis; Stergios Oikonomidis; Spyros Karkabounas
Electromagnetic Biology and Medicine | 2011
Angelos Evangelou; Ioannis Toliopoulos; Christos Giotis; Apostolos Metsios; Ioannis I. Verginadis; Yannis V. Simos; Konstantinos Havelas; Georgios Hadziaivazis; Spyridon Karkabounas
Journal of Musculoskeletal Research | 2014
Stergios Oikonomidis; Yannis V. Simos; Ioannis Toliopoulos; Ioannis I. Verginadis; Alexandros S. Oikonomidis; Vasilios Ragos; Spyridon Karkabounas; Angelos Evangelou
South Asian Journal of Experimental Biology | 2011
Vasilis Theoharis; Ioannis Toliopoulos; Yannis V. Simos; Apostolos Metsios; Ioannis Zelovitis; A. Tzora; Roman Liasko; Ioannis Skoufos; Spiros Karkabounas
Archive | 2013
Yannis V. Simos; Ioannis Toliopoulos; Ioannis I. Verginadis; Ilias V Karagounis; Pavlos S. Charalampidis; Vasilios Ragos; Angelos Evangelou; Spiros Karkabounas